



This document must not be published, distributed or circulated, directly or indirectly, in the United States of America, Canada, Australia or Japan.

Press release

SUCCESS OF THE €4 MILLION CAPITAL INCREASE

Transaction fully subscribed

Settlement delivery of new shares on 28 December 2018

Dijon, 21 December 2018

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations, today announces the success of its capital increase in cash with preferential subscription rights (the “Capital Increase”).

Patrick Alexandre, CEO of Crossject, said:

“In a difficult market environment, we are proud to announce the full completion of the capital increase launched on 3 December. We are delighted with the success of the transaction, which demonstrates the confidence of our shareholders and the quality of our project, namely to become the leader in self-administered emergency medicines.

I would like to thank all of our shareholders for their participation, which contributed to the success of the transaction, and in particular Gemmes Venture, our long-standing shareholder, for its support. With their loyalty and their renewed confidence, we will be able to meet the challenges of a new year that promises to be rich in events.”

The purpose of the Capital Increase is to finance the development of the Company and to strengthen its financial structure. Indeed, the activity requires recurrent investments to finance both the development and structuring of industrial facilities and the completion of the regulatory steps needed to obtain marketing authorisations (MAs), with first filings in the US and Europe scheduled in 2020, in priority for ZENEO® Midazolam, ZENEO® Naloxone and ZENEO® Adrenaline.

The final gross amount of the Capital Increase (share premium included) was €3.94 million, and resulted in the issuance of 3,400,842 new shares (the “New Shares”).

- 2,319,882 New Shares were subscribed by irrevocable entitlement (*à titre irréductible*), representing 68.21% of the New Shares;
- The additional demand, relating to 1,080,960 New Shares, will be fully allocated. Demand subject to reduction (*à titre réductible*) and free subscriptions, which represent more than €1.2 million, show that Crossject can count on the support of its main investors or sponsors, even in a difficult context. The transaction was accordingly performed in full.

In accordance with its commitment, leading shareholder GEMMES VENTURE subscribed for 1,656,077 New Shares, of which 835,035 shares through the exercise of Preferential Subscription Rights, in an aggregate amount of €1,921,049. GEMMES VENTURE accordingly holds 30.6% of the share capital of the Company after completion of the Capital Increase.

Following the Capital Increase, the Company's share capital will be €13,603,370, divided into 13,603,370 shares with a par value of €1.00 each.

The settlement of the New Shares and their admission to trading on Euronext Growth will take place on 28 December 2018. The New Shares will carry rights to all dividend payments made by the Company as from the date of their issue. As soon as they are issued, they will be immediately fungible with existing shares of the Company, and will be traded on the same line under the ISIN code FR0011716265.

Crossject was advised by CM-CIC Market Solutions and D'Hoir Beaufre Associés.

Public information

Pursuant to the provisions of Article L. 411-2 of the French Monetary and Financial Code and Article 211-2 of the AMF General Regulation, this issue did not give rise to the release of a Prospectus approved by the AMF, as the total amount of the offer was less than €8,000,000 (calculated over a period of 12 months).

Investors should refer to the risk factors described in the 2017 Financial Report available on the Company's website: www.crossject.com).



This document must not be published, distributed or circulated, directly or indirectly, in the United States of America, Canada, Australia or Japan.

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CM-CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cmcic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Audrey Lachat +33 (0)3 80 43 54 89
audrey.lachat@buzzetcompagnie.com

About CROSSJECT · www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, severe migraine, allergic shock, overdose and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and has notably received financing from Bpifrance.

Disclaimer

This press release may contain forward-looking information. This information is based either on trends or objectives, and should not be taken as a forecast of future performance or any other performance indicator. This information is inherently subject to risks and uncertainties, which may in certain cases be beyond the company's control, particularly in the context of an R&D process. A more detailed description of these risks and uncertainties can be found in the company's annual financial report, which is available on its website (www.crossject.com).

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.